IO Biotech announced the appointment of Helen Collins, MD, to its board of directors. Dr. Collins is an industry veteran with significant experience in oncology/hematology drug development and will serve on the Research and Development Committee of the Board. Dr. Collins joins the IO Biotech board of directors with more than 25 years of medical experience. She is currently the Chief Medical Officer at Enliven Therapeutics.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on IOBT:
- IO Biotech Announces 2023 Third Quarter Results
- IO Biotech completes enrollment in Phase 3 trial of advanced melanoma
- IO Biotech Announces Participation in Upcoming Investor Conferences
- IO Biotech presents three posters at SITC meeting
- IO Biotech Presents Three Posters at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
